摘要
目的分析达格列净联合利司美格鲁肽治疗2型糖尿病伴肥胖的疗效,以及对患者胰岛素抵抗,血清超敏C反应蛋白(hs-CRP),白细胞介素1β(IL-1β),肿瘤坏死因子-α(TNF-α)水平影响。方法选取本院2021年7月-2022年7月间88例2型糖尿病伴肥胖患者作为观察对象,按照治疗方法不同,分为对照组(行单一利司美格鲁肽治疗)和观察组(行达格列净联合利司美格鲁肽治疗),各44例,比较应用效果。结果观察组治疗总有效率高于对照组(P<0.05),观察组HOMA-IR(胰岛素抵抗指数)低于对照组,HOMA-B(胰岛B细胞功能指数)高于对照组(P<0.05),观察组空腹血糖、餐后2h血糖低于对照组(P<0.05),观察组hs-CRP、IL-1β、TNF-α水平低于对照组(P<0.05)。结论达格列净、利司美格鲁肽联合应用,可更好地稳定糖尿病患者血糖水平,改善胰岛素抵抗与炎症反应,增强临床效果。
Objective To analyze the efficacy of Dapagliflozin combined with rismegglutide in the treatment of type 2 diabetes with obesity,as well as insulin resistance,serum high-sensitivity C-reactive protein(hs CRP),interleukin-1β(IL-1β),Tumor Necrosis Factor-α(TNF-α)Horizontal impact.Methods From July 2021 to July 2022,88 patients with type 2 diabetes and obesity in our hospital were selected as the observation objects.According to the different treatment methods,they were divided into the control group(treated with single rismegglutide)and the observation group(treated with Dapagliflozin combined with rismegglutide),44 cases in each group,and the application effects were compared.Results The total effective rate of the observation group was higher than that of the control group(hs-CRP、IL-1β、TNF-αThe level was lower than that of the control group(P<0.05).Conclusion The combination of Dapagliflozin and rismegglutide can better stabilize the blood sugarlevel ofdiabetes patients,improve insulin resistance and inflammatory reaction,and enhance the clinical effect.
作者
陈柳
CHEN Liu(People's Hospital of Garze Tibetan Autonomous Prefecture,Garze Tibetan Autonomous Prefecture,Sichuan 626099,China)
出处
《中国国境卫生检疫杂志》
CAS
2023年第S01期1-3,共3页
Chinese Journal of Frontier Health and Quarantine
